natgillin/translations-raw huggingface dataset:
Melovem is used in cattle, together with appropriate antibiotic therapy, to reduce the signs of acute respiratory infections (infection of the lung and airways).
Pri govedu se zdravilo Melovem uporablja skupaj z ustreznim antibiotičnim zdravljenjem za zmanjšanje znakov akutne okužbe dihal (okužbe pljuč in dihalnih poti).
Melovem must not be used in animals with liver, heart or kidney problems, bleeding disorders, or suffering from irritation or ulcers of the digestive tract.
Zdravilo Melovem se ne sme uporabljati pri živalih, ki imajo težave z jetri, srcem ali ledvicami, motnje strjevanja krvi, razdražena prebavila ali razjede v prebavilih.
Studies have been carried out, both in calves and in pigs, to show that Melovem is bioequivalent to the reference medicine, Metacam.
Izvedene so bile študije pri govedu in prašičih, v katerih so proučevali, ali je zdravilo Melovem biološko enakovredno referenčnemu zdravilu Metacam.
Therefore, the CVMP's view was that, as for Metacam, Melovem's benefits are greater than its risks for the approved indications and the Committee recommended that Melovem be given a marketing authorisation.
Zato je menil, da so njegove koristi, tako kot pri zdravilu Metacam, večje od z njim povezanih tveganj pri uporabi za odobrene indikacije, in priporočil, da se zanj odobri dovoljenje za promet.
Why has Melovem been approved?
Zakaj je bilo zdravilo Melovem odobreno?
It can be used in combination with oral rehydration therapy (medicines given by mouth to restore water levels in the body) for diarrhoea in calves of over one week of age and young, non-lactating cattle.
Uporablja se lahko tudi v kombinaciji s peroralno rehidracijo (zdravili, ki jih žival zaužije za vzpostavitev ustrezne ravni vode v telesu) za zdravljenje driske pri teletih, starejših od enega tedna, ter pri mladem govedu zunaj obdobja laktacije.
The 5 mg/ml solution for injection can be used for the relief of post-operative pain associated with minor soft tissue surgery such as castration (surgical removal of the testicles).
Raztopina za injiciranje v odmerku 5 mg/ml se lahko uporablja za ublažitev pooperativnih bolečin, povezanih z manjšimi kirurškimi posegi na mehkih tkivih, kot je npr. kastracija (kirurška odstranitev mod).
Melovem is a medicine that contains the active substance meloxicam.
Melovem je zdravilo, ki vsebuje zdravilno učinkovino meloksikam.
Melovem solution for injection (5 mg/ml, 20 mg/ml and 30 mg/ml) is used in pigs to reduce the symptoms of lameness (inability to walk normally) and inflammation in non-infectious locomotor disorders (diseases that affect the ability to move).
Pri prašičih se raztopina za injiciranje zdravila Melovem (5 mg/ml, 20 mg/ml in 30 mg/ml) uporablja za zmanjšanje simptomov šepavosti (nezmožnosti normalne hoje) in vnetja pri neinfekcijskih boleznih gibal (boleznih, ki vplivajo na zmožnost gibanja).
Melovem solution for injection (20 mg/ml) is used in horses to relieve colic (abdominal pain) and the inflammation and pain in musculo-skeletal disorders.
Raztopina za injiciranje zdravila Melovem (20 mg/ml) se uporablja pri konjih za lajšanje kolike (trebušnih bolečin) ter ublažitev vnetja in bolečin pri kostno-mišičnih obolenjih.
What is Melovem used for?
Za kaj se zdravilo Melovem uporablja?
The 20 mg/ml and 30 mg/ml solution for injection can be used together with appropriate antibiotic therapy for the treatment of diseases that occur after farrowing (giving birth) such as puerperal septicaemia (bacteria present in blood) and toxaemia (a toxic state) (mastitismetritis-agalactia syndrome).
30 mg/ml se lahko v kombinaciji z ustreznimi antibiotiki uporablja za zdravljenje bolezni po oprasitvi (kotitvi mladičev), kot so puerperalna septikemija (prisotnost bakterije v krvi) in toksemija (sindrom mastitis-metritis-agalaktija).
How has Melovem been studied?
Kako je bilo zdravilo Melovem raziskano?
Melovem is a ‘generic'.
Zdravilo Melovem je „generično zdravilo“.
How does Melovem work?
Kako zdravilo Melovem deluje?
The 20 mg/ml and 30 mg/ml solutions for injection are also used in combination with antibiotic therapy to treat acute mastitis (inflammation of the udder).
Raztopina za injiciranje v odmerku 20 in 30 mg/ml se v kombinaciji z antibiotičnim zdravljenjem uporablja tudi za zdravljenje akutnega mastitisa (vnetja vimena).
While the reference medicine, Metacam, is available as 5 mg/ml and 20 mg/ml solutions for injection, Melovem is also available as a 30 mg/ml solution for injection.
Referenčno zdravilo Metacam je na voljo v obliki raztopine za injiciranje v odmerku 5 mg/ml in 20 mg/ml, zdravilo Melovem pa tudi v odmerku 30 mg/ml.
A slight temporary swelling at the injection site following injection under the skin and in the muscle was observed in cattle and pigs.
Pri govedu in prašičih so opazili blago prehodno oteklino na mestu injiciranja v podkožje in mišico.
What is Melovem?
Kaj je zdravilo Melovem?
Number (%)
Število (%)
The above are some reasons why this product may not be suitable for you.
Zgoraj so navedeni nekateri razlogi, zakaj to zdravilo za vas mogoče ni primerno.
if you are pregnant or could still become pregnant.
če ste noseči ali bi še vedno lahko zanosili.
If you forget to take a tablet, take it as soon as you remember.
Če ste pozabili vzeti tableto, jo vzemite takoj, ko se spomnite.
Urine parameters were pathologically changed.
Urinski parametri so bili patološko spremenjeni.
The clinical relevance of these changes has not been established.
Kliničnega pomena teh sprememb niso ugotovili.
Relative risk reduction (95% CI)
Zmanjšanje relativnega tveganja (95 % IZ)
It works by slowing or stopping the thinning of bone in these women.
Deluje tako, da upočasni ali zaustavi tanjšanje kosti pri teh ženskah.
While very infrequent, these clots can cause serious medical problems, disability or death.
Ti strdki so sicer zelo redki, lahko pa povzročijo hude zdravstvene težave, invalidnost ali smrt.
This lipid profile was maintained throughout the 7 years of treatment.
Ta profil lipidov se je ohranjal v vseh sedmih letih zdravljenja.
This must be investigated by your doctor.
Tako krvavitev mora raziskati vaš zdravnik.
Serious side effects - Stop taking CONBRIZA and see a doctor immediately
Resni neželeni učinki - Prenehajte jemati zdravilo CONBRIZA in nemudoma poiščite zdravnika
Date of latest renewal: 17 April 2014
Datum prve odobritve: 17. april 2009 Datum zadnjega podaljšanja: 17. april 2014
There is no evidence of endometrial proliferation.
Ni dokazov za proliferacijo endometrija.
In the case of overdose, there is no specific antidote, and treatment should be symptomatic.
V primeru prevelikega odmerjanja ni specifičnega antidota, zdravljenje naj bo simptomatsko.
Adverse reactions are categorized according to the following frequencies: very common ( 1/10); common ( 1/100 to  1/10); uncommon ( 1/1,000 to  1/100); rare ( 1/10,000 to  1/1,000); not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni glede na naslednje pogostnosti: zelo pogosti ( 1/10); pogosti ( 1/100 do  1/10); občasni ( 1/1.000 do  1/100); redki ( 1/10.000 do  1/1.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
You can also report side effects directly via the national reporting system listed in Appendix V.By reporting side effects you can help provide more information on the safety of this medicine.
O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V.S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
This medicine should not be used for the treatment of osteoporosis in men.
To zdravilo se ne sme uporabljati za zdravljenje osteoporoze pri moških.
Do not take this medicine if you are breast-feeding, because it is not known whether it is excreted in mother's milk.
Ne jemljite tega zdravila, če dojite, ker ni znano, ali se izloča v materino mleko.
Therefore, bazedoxifene is not recommended for treatment or prevention of breast cancer.
Zato bazedoksifena ne priporočajo za zdravljenje ali preprečevanje raka dojk.
if you are allergic to bazedoxifene or any of the other ingredients of this medicine (listed in section 6).
če ste alergični na bazedoksifen ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
if you have active uterine cancer.
če imate aktivnega raka maternice.
Doses higher than 20 mg are not recommended because there is no demonstrable increased efficacy and higher doses may be associated with additional risk (see section 5.1).
Odmerki, ki presegajo 20 mg, niso priporočljivi, ker zanje ni bila dokazana povečana učinkovitost, večji odmerki pa so lahko povezani z dodatnim tveganjem (glejte poglavje 5.1).
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo.
if you have liver or severe kidney problems.
če imate težave z jetri ali hude težave z ledvicami.
if you are suffering from breast cancer, as there is insufficient experience with this medicine use in women with this disease.
če imate raka dojk, ker z uporabo tega zdravila pri ženskah s to boleznijo ni dovolj izkušenj.
Hypromellose Titanium dioxide (E171) Macrogol 400
hipromeloza titanov dioksid (E171) makrogol 400
Discontinuation from the study was required when excessive bone loss or incident vertebral fractures occurred.
Izključitev iz študije je bila potrebna, kadar je prišlo do čezmerne izgube kostnine ali naključnih zlomov vretenc.
You can take the tablet at any time of the day, with or without food.
Tableto lahko zaužijete ob poljubnem dnevnem času, s hrano ali brez nje.
Multiple dose 20 mg/day 6.2 ± 2.2 1.7 ± 1.8 28 ± 11 82 ± 37 4.1 ± 1.7
Večkratni odmerki 20 mg/dan 6,2 ± 2,2 1,7 ± 1,8 28 ± 11 82 ± 37 4,1 ± 1,7
The mean 10-year fracture probability of a major osteoporotic fracture for the entire study population was 11%.
Povprečna 10-letna verjetnost večjega zloma zaradi osteoporoze za celotno populacijo v raziskavi je bila 11 %.
The recommended dose of CONBRIZA is one tablet once daily, at any time of day, with or without food (see section 5.2).
Priporočeni odmerek zdravila CONBRIZA je ena tableta enkrat na dan, ne glede na dnevni čas, s hrano ali brez nje (glejte poglavje 5.2).
In order for this medicine to treat osteoporosis, it must be taken daily.
Če naj to zdravilo zdravi osteoporozo, ga morate jemati vsak dan.
Speak with your doctor to see if you are at increased risk for blood clots.
Pogovorite se zzdravnikom, da boste izvedeli, ali je pri vas zvečano tveganje za nastanek krvnih strdkov.
If you need to remain immobile for an extended period of time or are scheduled to have surgery, it is important for you to talk to your doctor about ways you can reduce the risk of blood clots.
Če se daljši čas ne morete gibati ali je pri vas predvidena operacija, je pomembno, da se pogovorite z zdravnikom o tem, kako lahko zmanjšate nevarnost nastanka krvnih strdkov.
This medicine contains lactose (a type of sugar).
To zdravilo vsebuje laktozo (vrsta sladkorja).
In addition, women taking CONBRIZA should be advised to move about periodically during prolonged travel.
Poleg tega je treba ženskam, ki jemljejo zdravilo CONBRIZA, svetovati, naj se med daljšimi potovanji občasno sprehodijo.
If any of them apply to you, talk to your doctor before you take the medicine.
Če katerikoli od njih velja za vas, se pogovorite z zdravnikom, preden zdravilo vzamete.
Manufacturer: PfizerIrelandPharmaceuticals, Little Connell,Newbridge, County Kildare, Ireland.
Izdelovalec: Pfizer Ireland Pharmaceuticals, Little Connell, Newbridge, County Kildare, Irska.
However, if it is almost time to take your next dose of this medicine, skip the dose you missed and only take your next scheduled dose.
Če pa je že skoraj čas za naslednji odmerek tega zdravila, pozabljenega izpustite in vzemite šele naslednji odmerek po razporedu.
No dose adjustment is necessary based on age.
Prilagajanje odmerka na podlagi starosti ni potrebno.
if you are pre-menopausal.
če še niste v menopavzi.
Total number of subjects n=1,724 n=1,741
Celotno število oseb n = 1.724 n = 1.741
7 film-coated tablets 28 film-coated tablets 30 film-coated tablets 84 film-coated tablets 90 film-coated tablets
7 filmsko obloženih tablet 28 filmsko obloženih tablet 30 filmsko obloženih tablet 84 filmsko obloženih tablet 90 filmsko obloženih tablet
Other venous thromboembolic events could also occur.
Možni so tudi drugi venski trombembolični dogodki.
If you are traveling on long trips, you should walk around or exercise your legs and feet at regular intervals.
Na dolgih potovanjih se morate sprehajati ali si v rednih presledkih razgibavati nogein stopala.
Patients with signs or symptoms of endometrial cancer; safety in this patient group has not been adequately studied.
Bolnice z znaki ali simptomi raka endometrija; pri tej skupini bolnic varnosti niso dovolj proučili.
What CONBRIZA is and what it is used for
Kaj je zdravilo CONBRIZA in za kaj ga uporabljamo
d p-value=0.035
d vrednost p = 0,035
The safety data in the following table are derived from both clinical trials and spontaneous post-marketing reporting.
Podatki o varnosti v spodnji preglednici izvirajo iz kliničnih preskušanj in tudi iz spontanih poročil v obdobja trženja zdravila.
EU/1/09/511/001 28 tablets EU/1/09/511/002 30 tablets EU/1/09/511/003 84 tablets EU/1/09/511/004 90 tablets EU/1/09/511/005 7 tablets
EU/1/09/511/001 28 tablet EU/1/09/511/002 30 tablet EU/1/09/511/003 84 tablet EU/1/09/511/004 90 tablet EU/1/09/511/005 7 tablet
Not known (frequency cannot be estimated from the available data):
Neznana (ni mogoče oceniti iz razpoložljivih podatkov):
The 3-year core study was extended twice, with two 2-year double-blind, placebocontrolled extensions, resulting in a total treatment duration of up to 7 years (7-year study).
Triletna temeljna študija je bila dvakrat podaljšana z 2-letnimi, dvojno slepimi, s placebom nadzorovanimi podaljšanji, s čimer je skupen čas trajanja znašal do 7 let (7-letna študija).
Mean ± SD pharmacokinetic parameters of bazedoxifene (n=23) Cmax (ng/ml)
Povprečje ± SD farmakokinetičnih parametrov bazedoksifena (n = 23) Cmax (ng/ml)
CONBRIZA should be discontinued prior to and during prolonged immobilisation (e.g., post-surgical recovery, prolonged bed rest), and therapy should be resumed only after the patient is fully ambulatory.
Zdravilo CONBRIZA je treba ukiniti pred in med dolgotrajno imobilizacijo (npr. okrevanje po operaciji, dolgotrajno ležanje v postelji), zdravljenje pa se sme ponovno uvesti šele, ko je bolnica spet povsem pokretna.
Other medicines and CONBRIZA
Druga zdravila in zdravilo CONBRIZA
If such symptoms occur, patients should avoid driving or use of machines that requires accurate visual perception until symptoms have resolved, or until they have received medical advice that it is safe to do so.
Če se taki simptomi pojavijo, se naj bolnice izogibajo vožnji ali upravljanju s stroji, ki zahtevajo natančno vidno zaznavo, dokler simptomi ne izzvenijo ali dokler jim zdravnik ne svetuje, da je tako početje varno.
Each film-coated tablet contains 142.8 mg lactose (as monohydrate).
Ena filmsko obložena tableta vsebuje 142,8 mg laktoze (v obliki monohidrata).
The median T-score ranged from -0.6 to -1.4, depending on the skeletal site.
Mediana ocena T je segala od -0,6 do -1,4, odvisno od lokacije v skeletu.
if you have had increased levels of triglycerides (a type of fat found in your blood) in the past.
če ste kdaj prej imeli zvišano raven trigliceridov (vrsta maščob v vaši krvi).
In subjects treated with bazedoxifene, the incidence of fractures was related to the baseline fracture risk: the higher the fracture risk, the greater the benefit with bazedoxifene treatment.
Pri osebah, zdravljenih z bazedoksifenom, je bila pojavnost zlomov povezana s tveganjem izhodiščnega zloma: čim večja je bila nevarnost zloma, tem večja je bila korist zdravljenja z bazedoksifenom.
Because these changes are not considered clinically relevant, bazedoxifene can be administered without regard to meals.
Ker te spremembe ne veljajo za klinično pomembne, lahko dajemo bazedoksifen ne glede na obroke.
In long-term studies renal tumours (adenomas and carcinomas) were observed at all doses tested, most likely as a consequence of this chronic renal damage.
V dolgoročnih študijah so pri vseh preskušanih odmerkih opazili ledvične tumorje (adenome in karcinome), ki so najverjetneje nastali zaradi teh kroničnih ledvičnih okvar.
The major route of excretion of radio-labelled bazedoxifene is the faeces, and less than 1% of the dose is eliminated in urine.
Poglavitna pot odstranjevanja radioaktivno označenega bazedoksifena iz telesa je z blatom, z urinom se izloči manj kot 1 % odmerka.
Bazedoxifene does not induce or inhibit the activities of major CYP isoenzymes.
Bazedoksifen niti ne inducira niti ne inhibira aktivnosti poglavitnih izoencimov CYP.
c p-value=0.22
c vrednost p = 0,22
In clinical trials, somnolence was reported as an adverse reaction, and patients should be advised on the potential effect on driving and using machines.
V kliničnih preskušanjih so poročali o zaspanosti kot neželenem učinku, zato je treba bolnice opozoriti na možne učinke na sposobnost vožnje in upravljanja s stroji.
Uncommon Frequency not known (cannot be estimated from available data)
Neznana (ni mogoče oceniti iz razpoložljivih podatkov)
They are packed in PVC/Aclar blisters and are available in packs of 7, 28, 30, 84 or 90 tablets.
Pakirane so v pretisnih omotih iz PVC/Aclar, na voljo pa so v pakiranjih po 7, 28, 30, 84 ali 90 tablet.
You should continue taking this medicine as long as your doctor tells you to.
To zdravilo morate jemati toliko časa, kot vam je naročil zdravnik.
CONBRIZA is only indicated for use in postmenopausal women (see section 4.3) and should not be used during breast-feeding.
Zdravilo CONBRIZA je indicirano le za uporabo pri ženskah v postmenopavzi (glejte poglavje 4.3) in se ga med dojenjem ne sme uporabljati.
This pharmacological effect of bazedoxifene can also be expected in pre-menopausal women, but is considered clinically irrelevant in post-menopausal women.
Ta farmakološki učinek bazedoksifena lahko pričakujemo tudi pri ženskah pred menopavzo, vendar velja pri ženskah po menopavzi za klinično nepomembnega.
Table 1: Effect of bazedoxifene on risk of vertebral fractures after 3 years of treatment Number of subjects
Preglednica 1: Učinek bazedoksifena na tveganje za zlome vretenc po 3 letih zdravljenja Število oseb
Its safety in premenopausal women has not been established, and its use is not recommended in this population.
Njegove varnosti za ženske pred menopavzo niso dokazali in uporaba tega zdravila pri tej populaciji ni priporočljiva.
If you feel drowsy after taking this medicine, you should avoid driving or operating machines.
Če ste po jemanju tega zdravila zaspani, ne upravljajte vozil ali strojev.
Since chronic progressive nephropathy and corticomedullar nephrocalcinosis are most likely rat-specific nephropathies, these findings are presumably not relevant for humans.
Ker sta kronična progresivna nefropatija in kortikomedularna nefrokalcinoza najverjetneje za podgane specifični nefropatiji, te ugotovitve za ljudi verjetno niso relevantne.
All subjects received calcium supplementation daily; most received 600 mg calcium (e.g., Caltrate) daily, while some received up to 1,200 mg daily.
Vse osebe so vsak dan prejemale dodatke kalcija; večina jih je prejemala po 600 mg kalcija (npr. Caltrate) na dan, nekatere pa do 1.200 mg na dan.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolnice z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze-galaktoze ne smejo jemati tega zdravila.
This increase was most likely attributed to age-related changes in hepatic function.
Ta porast lahko najverjetneje pripišemo starostnim spremembam delovanja jeter.
What you need to know before you take CONBRIZA
Kaj morate vedeti, preden boste vzeli zdravilo CONBRIZA
These tumours are considered as spontaneous renal cell carcinomas that are known to occur in nonhuman primates and are unlikely to be relevant to humans.
Ti tumorji veljajo za spontane karcinome ledvičnih celic, za katere je znano, da se pojavljajo pri primatih, razen pri človeku, in ni verjetno, da bi bili relevantni za ljudi.
Following intravenous administration of a 3 mg dose of bazedoxifene, the volume of distribution is 14.7 ± 3.9 l/kg.
Po intravenski aplikaciji 3 mg odmerka bazedoksifena je volumen porazdelitve 14,7 ± 3,9 l/kg.
Pharmacotherapeutic group: Selective estrogen receptor modulator, ATC code: G03XC02.
Farmakoterapevtska skupina: selektivni modulator estrogenskih receptorjev (SERM); oznaka ATC: G03XC02.
A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.
Dokazali so pomembno zmanjšanje incidence zlomov vretenc; učinkovitosti za zlome kolka niso dokazali.
If this happens, you should avoid driving or operating machines until your doctor tells you that it is safe to do so.
Če se pojavijo, ne vozite in upravljajte s stroji, dokler vam zdravnik ne pove, da je tako početje varno.
Histological assessment of bone biopsies from all treatment groups revealed formation of normal lamellar bone in all treated subjects.
Histološki pregled kostnih biopsij iz vseh zdravljenih skupin je pri vseh zdravljenih osebah pokazal oblikovanje normalne lamelarne kosti.
The concentrations of this glucuronide are approximately 10-fold higher than those of unchanged active substance in plasma.
Koncentracija tega glukuronida v plazmi je približno 10-krat višja od koncentracije nespremenjene zdravilne učinkovine.
CONBRIZA has minor influence on the ability to drive and use machines.
Zdravilo CONBRIZA ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
In subjects with 10-year fracture probabilities at or above 16%, bazedoxifene was associated with a significant decrease in the risk of all clinical fractures.
Pri osebah z 10-letno verjetnostjo zloma 16 % ali več je bil bazedoksifen povezan s pomembnim zmanjšanjem tveganja vseh kliničnih zlomov.
All subjects were to receive 1,200 mg of elemental calcium and 400 IU of vitamin D daily.
Vse osebe v raziskavi so prejemale po 1.200 mg elementarnega kalcija in po 400 i.e. vitamina D na dan.
Bazedoxifene is highly bound (98% - 99%) to plasma proteins in vitro.
Bazedoksifen se in vitro v veliki meri (98 % - 99 %) veže na plazemske beljakovine.
Any uterine bleeding during CONBRIZA therapy is unexpected and should be fully investigated.
Morebitna maternična krvavitev med zdravljenjem z zdravilom CONBRIZA ni pričakovana in jo je treba podrobno raziskati.
This is because sitting for a long time in the same position may prevent good blood circulation and may increase your risk of blood clots.
Dolgotrajno sedenje v istem položaju lahko namreč poslabša krvni obtok in zveča nevarnost krvnih strdkov.
The rate of VTE was highest in the first year with a relative risk of 2.69.
Delež VTE je bil največji v prvem letu, pri čemer je relativno tveganje znašalo 2,69.
as it may increase your risk of getting blood clots.
ker lahko zveča nevarnost nastanka krvnih strdkov.
Histomorphometric assessment revealed normal mineralisation, as evidenced by the presence of normal osteoid thickness, normal mineralisation lag time, and mineral apposition rate.
Histomorfometrični pregled je pokazal normalno mineralizacijo, na katero so kazali prisotnost normalne debeline osteoida, normalnega časa zaostajanja mineralizacije in hitrosti nalaganja mineralov.
The bazedoxifene 40 mg dose was decreased to a 20 mg dose after approximately 4 years.
Odmerek bazedoksifena se je zmanjšal iz 40 mg na 20 mg po približno 4 letih.
These effects on bone remodeling lead to an increase in bone mineral density (BMD), which in turn contributes to a reduction in the risk of fractures.
Ti učinki na preoblikovanje kosti zvečajo mineralno kostno gostoto (MKG), ki nato prispeva k zmanjšanju nevarnosti kostnih zlomov.